Nintedanib plus pemetrexed/cisplatin in patients with malignant pleural mesothelioma: phase II results from the randomized, placebo-controlled LUME-Meso trial - Grosso, F; Steele, N; Novello, S (J Clin Oncol, 2017)
, et al.